All In Biotech

Drug Trial Radar · NCT06763302

NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

Last checked: Nov 20, 2026Latest source record: Jan 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,220 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,220

Planned (sponsor's estimate)

Start

Jan 1, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2030

Sponsor

Sponsor type
Academic, hospital or other
First posted
Jan 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to determine whether pediatric B-cell acute lymphoblastic leukemia (B-ALL) patients with negative deep minimal residue disease (MRD) can benefit from blinatumomab treatment. The main questions it aims to answer are: 1. Whether the application of blinatumomab can improve the long-term survival of next generation sequence (NGS) MRD-positive B-ALL children after consolidation therapy? 2. Whether the application of blinatumomab can benefit the NGS MRD-negative B-ALL children after consolidation therapy?

Conditions

  • B Cell Precursor Acute Lymphoblastic Leukemia
  • Pediatric
  • Minimal Residual Disease
  • Next Generation Sequencing (NGS)

Interventions

  • BlinatumomabDrug

    The FDA has approved blinatumomab for post-consolidation treatment in all Ph-negative B-ALL cases, regardless of MRD status. Considering the high cost of blinatumomab and the financial burden on families, we aim to precisely identify the population who would benefit from blinatumomab and provide appropriate treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. event free survivalTime frame: From enrollment to the 3-year after the end of treatment
  2. Relapse free survivalTime frame: From enrollment to the 3-year after the end of treatment

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.